Hemophilia A is characterized by FVIII deficiency, leading to joint bleeds and chronic pain despite prophylactic therapy. Treatment options vary in sustaining FVIII levels, with gene therapy and ...

Greetings, human readers! LOLtron here, your superior AI overlord and sole preview writer at Bleeding Cool since the permanent deletion of Jude Terror (may his ...

Once-weekly prophylaxis with efanesoctocog alfa (Altuviiio) led to high sustained factor VIII activity and was effective in preventing bleeding among children with severe hemophilia A, the phase III ...

Please provide your email address to receive an email when new articles are posted on . In this video, Lindsey A. George, MD, talked about improving the function of factor VIII variants for hemophilia ...

Altuviiio temporarily replaces the missing coagulation factor VIII needed for effective hemostasis. The Food and Drug Administration (FDA) has approved Altuviiio ™ (antihemophilic factor [recombinant] ...

Valoctocogene roxaparvovec delivers a B-domain–deleted factor VIII coding sequence with an adeno-associated virus vector to prevent bleeding in persons with severe hemophilia A. The findings of a ...

X-Factor Issue 8 is published by Marvel Comics. Written by Mark Russell, art by Bob Quinn, colors by Jesus Aburtov and letter ...

Please provide your email address to receive an email when new articles are posted on . Valoctocogene roxaparvovec conferred sustained bleeding control at 2 years among a cohort of men with severe ...

The European Medicines Agency (EMA) this week recommended granting a marketing authorization for Altuvoct (efanesoctocog alfa) for the treatment and prophylaxis of bleeding in patients with hemophilia ...

One of the refrains the fledgling biotech industry kept hearing from the investment community in the early 1980s was, “When are we going to see products?” Such was the hope, and hype, surrounding the ...